Company’s 36-month beta value is -1.40.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLNO is 21.26M, and currently, short sellers hold a 14.96% ratio of that floaft. The average trading volume of SLNO on May 27, 2024 was 434.76K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SLNO) stock’s latest price update
Soleno Therapeutics Inc (NASDAQ: SLNO)’s stock price has decreased by -0.02 compared to its previous closing price of 41.17. However, the company has seen a -10.83% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-05-22 that REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that data from the randomized withdrawal period of Study C602 of DCCR (diazoxide choline) extended-release tablets in Prader-Willi Syndrome (PWS) will be featured in an oral presentation at the Annual Meeting of the Endocrine Society (ENDO 2024), being held June 1-4, 2024 in Boston, Massachusetts.
SLNO’s Market Performance
Soleno Therapeutics Inc (SLNO) has seen a -10.83% fall in stock performance for the week, with a 10.23% gain in the past month and a -20.08% plunge in the past quarter. The volatility ratio for the week is 5.37%, and the volatility levels for the past 30 days are at 6.42% for SLNO. The simple moving average for the last 20 days is -8.56% for SLNO stock, with a simple moving average of 27.56% for the last 200 days.
Analysts’ Opinion of SLNO
Many brokerage firms have already submitted their reports for SLNO stocks, with Robert W. Baird repeating the rating for SLNO by listing it as a “Outperform.” The predicted price for SLNO in the upcoming period, according to Robert W. Baird is $72 based on the research report published on May 10, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see SLNO reach a price target of $93. The rating they have provided for SLNO stocks is “Overweight” according to the report published on February 05th, 2024.
Stifel gave a rating of “Buy” to SLNO, setting the target price at $63 in the report published on January 23rd of the current year.
SLNO Trading at -2.90% from the 50-Day Moving Average
After a stumble in the market that brought SLNO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.52% of loss for the given period.
Volatility was left at 6.42%, however, over the last 30 days, the volatility rate increased by 5.37%, as shares surge +8.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.30% lower at present.
During the last 5 trading sessions, SLNO fell by -10.83%, which changed the moving average for the period of 200-days by +713.44% in comparison to the 20-day moving average, which settled at $45.18. In addition, Soleno Therapeutics Inc saw 2.26% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SLNO starting from Vivo Opportunity, LLC, who sale 351,242 shares at the price of $45.13 back on Apr 30 ’24. After this action, Vivo Opportunity, LLC now owns 7,316,851 shares of Soleno Therapeutics Inc, valued at $15,851,551 using the latest closing price.
Vivo Opportunity, LLC, the 10% Owner of Soleno Therapeutics Inc, sale 750,000 shares at $47.80 during a trade that took place back on Apr 29 ’24, which means that Vivo Opportunity, LLC is holding 7,668,093 shares at $35,850,000 based on the most recent closing price.
Stock Fundamentals for SLNO
Current profitability levels for the company are sitting at:
- -15.59 for the present operating margin
- 0.38 for the gross margin
The net margin for Soleno Therapeutics Inc stands at -15.1. The total capital return value is set at -0.35. Equity return is now at value -71.26, with -55.24 for asset returns.
Based on Soleno Therapeutics Inc (SLNO), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -88.59. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -475.32.
Currently, EBITDA for the company is -36.71 million with net debt to EBITDA at 0.82. When we switch over and look at the enterprise to sales, we see a ratio of 422.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.23.
Conclusion
In a nutshell, Soleno Therapeutics Inc (SLNO) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
